Lipodystrophy: The Metabolic Link of HIV Infection with Insulin-Resistance Syndrome

Freitas, Paula; Carvalho, Davide; Souto, Selma B.; Sarmento, António; Medina, José Luis Valdez

doi:10.5772/52685

Cited by 4 publications

(1 citation statement)

References 205 publications

(259 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results demonstrated benefits on both VATand SAT quality (density) independent of changes in adipose tissue quantity, with associated improvements in circulating adiponectin, total cholesterol and triglyceride concentrations, supporting the hypothesis that tesamorelin therapy could improve adipose tissue function. Although we did not demonstrate a significant correlation between improvements in VAT or SAT density and HOMA-IR in this analysis, insulin resistance in PWH is multifactorial [30], and in studies of both PWH and persons with diabetes, tesamorelin therapy has had a neutral effect on parameters of insulin glucose homeostasis [31,32]. As such, the lack of such a correlation in this analysis does not dampen our enthusiasm for our primary findings.…”

Section: Discussioncontrasting

confidence: 52%

Tesamorelin improves fat quality independent of changes in fat quantity

Lake

Erlandson

et al. 2021

Aids

View full text Add to dashboard Cite

Objectives: Fat quality and quantity may affect health similarly or differently. Fat quality can be assessed by measuring fat density on CT scan (greater density ¼ smaller, higher quality adipocytes). We assessed the effects of tesamorelin, a growth hormonereleasing hormone analogue that reduces visceral fat (VAT) quantity in some people living with HIV (PWH), on fat density.Design: Participants from two completed, placebo-controlled, randomized trials of tesamorelin for central adiposity treatment in PWH were included if they had either a clinical response to tesamorelin (VAT decrease !8%, %70% of participants) or were placebo-treated.Methods: CT VAT and subcutaneous fat (SAT) density (Hounsfield Units, HU) were measured by a central blinded reader.Results: Participants (193 responders, 148 placebo) were 87% male and 83% white. Baseline characteristics were similar across arms, including VAT (À91 HU both arms, P ¼ 0.80) and SAT density (À94 HU tesamorelin, À95 HU placebo, P ¼ 0.29). Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only [VAT: þ6.2 (8.7) HU tesamorelin, þ0.3 (4.2) HU placebo, P < 0.0001; SAT: þ4.0 (8.7) HU tesamorelin, þ0.3 (4.8) HU placebo, P < 0.0001]. The tesamorelin effects persisted after controlling for baseline VAT or SAT HU and area, and VAT [þ2.3 HU,3), P ¼ 0.001) or SAT (þ3.5 HU, 95% confidence interval (2.3-4.7), P < 0.001] area change. Conclusion:In PWH with central adiposity who experienced VAT quantity reductions on tesamorelin, VAT and SAT density increased independent of changes in fat quantity, suggesting that tesamorelin also improves VAT and SAT quality in this group.

show abstract

Section: Discussioncontrasting

confidence: 52%

Tesamorelin improves fat quality independent of changes in fat quantity

Lake

Erlandson

et al. 2021

Aids

View full text Add to dashboard Cite

show abstract

A leptina e o seu impacto metabólico nas lipodistrofias

Lau

Freitas

Oliveira

et al. 2014

Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo

View full text Add to dashboard Cite

Prevalence and characteristics of metabolic syndrome and its components among adults living with and without HIV in Nigeria: a single-center study

Jumare,

Dakum,

Sam-Agudu

et al. 2023

BMC Endocr Disord

View full text Add to dashboard Cite

Background Persons living with HIV (PLHIV) now live longer due to effective combination antiretroviral therapy. However, emerging evidence indicates that they may be at increased risk for some cardiometabolic disorders. We compared the prevalence of metabolic syndrome (MetS) and its component disorders between persons living with and without HIV in Nigeria. Methods This was a cross-sectional analysis of baseline data from a prospective cohort study of non-communicable diseases among PLHIV along with age- and sex-matched persons without HIV (PWoH) at the University of Abuja Teaching Hospital Nigeria. We collected sociodemographic and clinical data, including anthropometric measures and results of relevant laboratory tests. MetS was defined using a modification of the third report of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) criteria. Results Of the 440 PLHIV and 232 PWoH, women constituted 50.5% and 51.3% respectively. The median age of the PLHIV was 45 years while that of the PWoH was 40 years. The prevalence of MetS was 30.7% (95% CI: 26.4%, 35.2%) and 22.8% (95% CI: 17.6%, 28.8%) among the PLHIV and PWoH respectively (P = 0.026). Independent associations were found for older age (P < 0.001), female sex (P < 0.001), family history of diabetes (P < 0.001), family history of hypertension (P = 0.013) and alcohol use (P = 0.015). The prevalence of component disorders for PLHIV versus PWoH were as follows: high blood pressure (22.3% vs 20.3%), prediabetes (33.8% vs 21.1%), diabetes (20.5% vs 8.2%), high triglycerides (24.5% vs 17.2%), low HDL-Cholesterol (51.1% vs 41.4%), and abdominal obesity (38.4% vs 37.1%). Adjusting for age and sex, prediabetes, diabetes, and low HDL-Cholesterol were significantly associated with HIV status. Duration on antiretroviral therapy, protease inhibitor-based regimen, CD4 count, and viral load were associated with some of the disorders mostly in unadjusted analyses. Conclusion We found a high burden of MetS and its component disorders, with significantly higher prevalence of dysglycemia and dyslipidemia among PLHIV as compared to PWoH. Integration of strategies for the prevention and management of MetS disorders is needed in HIV treatment settings.

show abstract

Lipodystrophy: The Metabolic Link of HIV Infection with Insulin-Resistance Syndrome

Cited by 4 publications

References 205 publications

Tesamorelin improves fat quality independent of changes in fat quantity

Tesamorelin improves fat quality independent of changes in fat quantity

A leptina e o seu impacto metabólico nas lipodistrofias

Prevalence and characteristics of metabolic syndrome and its components among adults living with and without HIV in Nigeria: a single-center study

Contact Info

Product

Resources

About